Is the DEA's New "Prescription Series" Regulation Balanced?
Commentary (pdf)
DEA issues Federal Register with "Issuance of Multiple Prescriptions for Schedule II Controled Substances" regulation
- Notice (pdf)
Continuing Concerns About DEA's "Prescription Series" Proposal (commentary from Gilson and Joranson)
- Statement (pdf)
DEA issues "Clarification of Existing Requirements Under the Controlled Substances Act for Prescribing Schedule II Controlled Substances"
- Notice (pdf)
PPSG's Response to DEA's Solicitation of Comments
Letter (pdf)
DEA issues "Solicitation on Comments on Dispensing of Controlled Substances for the Treatment of Pain"
- Notice (pdf)
PPSG responds to the DEA;s Interim Policy Statement (IPS)
- Letter (pdf)
- DEA issues Federal Register w/ section (IPS) pertaining to the FAQ withdrawal (no longer available)
- Letter (pdf)
- PPSG issues news alert regarding removal of FAQ from website
- News Alert (pdf)
- DEA subsequently posts a statement of explanation on their website (no longer available)
PPSG receives letter from DEA requesting removal of FAQ from their website
- Letter (pdf)
Prescribing clarification from DEA; response to Heit and Joranson inquiry:
From time to time there are questions that physicians and pharmacists have about how federal controlled substances requirements pertain to specific situations, the answers to which may not be readily apparent in federal regulations. Recently, Dr. Howard Heit and David Joranson asked DEA for clarification about the practice of writing more than one prescription for a controlled substance at a time for a patient to cover an extended period of treatment. DEA provided its response, which can be accessed below.
- Letter (pdf)
A Joint Statement from 21 Health Organizations and the Drug Enforcement Administration - "Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act"
- Media Advisory (pdf)
- Joint Statement (pdf)